SBRT2015

Radiaton oncologists & risk of ‘bystander effect’

We have a continuous need to reflect on: • Clinical need for improved treatments? • Evidence for efficacy (clinical trials, CER)? • Treatment toxicities, especially use of patient reported outcomes (PRO’s) • Cost-effectiveness (incentives and hurdles)